Education
About Us
Working with TipRanks
Follow Us
NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
Carboplatin, Pembrolizumab, Paclitaxel, Nivolumab, Ipilimumab, Bevacizumab, Regorafenib, Neo212 Oral Capsule, Folfiri Protocol
Colorectal Cancer, Gastroesophageal Junction Adenocarcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Cervical Cancer, Gastric Cancer, Esophageal Cancer, Head And Neck Squamous Cell Carcinoma, Melanoma, Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma, Merkel Cell Carcinoma, Urothelial Carcinoma, Mismatch Repair Deficient Colorectal Cancer, Brain Metastases, Adult, Glioblastoma, Idh-Wildtype, Diffuse Astrocytoma, Idh-Mutant, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer
Phase I/II
Recruiting
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Aug 17, 2023
―
Neo100
Residual, Progressive Or Recurrent Grade Ii Or Iii Meningioma
Phase II
Recruiting
NEO100 and High-Grade Meningioma
Aug 20, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does NeOnc Technologies Holdings, Inc. (NTHI) have in its pipeline
NTHI is currently developing the following drugs: Carboplatin, Pembrolizumab, Paclitaxel, Nivolumab, Ipilimumab, Bevacizumab, Regorafenib, Neo212 Oral Capsule, Folfiri Protocol, Neo100, Perillyl Alcohol. These drug candidates are in various stages of clinical development as the company works toward FDA approval.